GPP
EPRX

Great Point Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Great Point Partners’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.69M Hold
1,200,000
– – 2% 20
2025
Q4 		$9.06M Hold
1,200,000
– – 2.94% 13
2025
Q3 		$7.08M Buy
+1,200,000
New +$6.53M 2.92% 14

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Great Point Partners's EPRX Position: Q1 2026 in Review

Great Point Partners held its Eupraxia Pharmaceuticals (EPRX) position steady in Q1 2026 at 1,200,000 shares worth $8.69M. The position accounts for 2% of the portfolio, ranked #20.

Great Point Partners first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.06M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Great Point Partners held 1,200,000 shares of Eupraxia Pharmaceuticals worth $8.69M as of Q1 2026.
  • Great Point Partners left its Eupraxia Pharmaceuticals share count unchanged in Q1 2026.
  • Eupraxia Pharmaceuticals made up 2% of Great Point Partners's portfolio in Q1 2026, its #20 holding.
  • Great Point Partners first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Great Point Partners's Eupraxia Pharmaceuticals position peaked at $9.06M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.